$3.39
4.24% yesterday
Nasdaq, Aug 25, 10:15 pm CET
ISIN
US02155H2004
Symbol
ALT

Altimmune Stock price

$3.54
-0.66 15.71% 1M
-2.57 42.06% 6M
-3.67 50.90% YTD
-3.22 47.63% 1Y
-14.16 80.00% 3Y
-18.45 83.90% 5Y
-233.76 98.51% 10Y
-233.76 98.51% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 0.28%
ISIN
US02155H2004
Symbol
ALT
Industry

Key metrics

Basic
Market capitalization
$312.4m
Enterprise Value
$143.7m
Net debt
positive
Cash
$183.1m
Shares outstanding
85.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
15,621.5 | 82,489.8
EV/Sales
7,183.0 | 37,930.0
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
88.7%
Return on Equity
-77.0%
ROCE
-52.1%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$20.0k | $3.8k
EBITDA
$-94.2m | $-109.3m
EBIT
$-94.4m | $-112.1m
Net Income
$-87.8m | $-95.9m
Free Cash Flow
$-81.6m
Growth (TTM | estimate)
Revenue
-95.1% | -81.0%
EBITDA
13.6% | -6.2%
EBIT
14.0% | -8.7%
Net Income
13.4% | -0.9%
Free Cash Flow
-14.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-471,205.0% | -2,885,686.7%
EBIT
-471,850.0%
Net
-438,730.0% | -2,531,708.5%
Free Cash Flow
-407,915.0%
More
EPS
$-1.1
FCF per Share
$-1.0
Short interest
32.0%
Employees
59
Rev per Employee
$0.0
Show more

Is Altimmune a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Altimmune Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Altimmune forecast:

11x Buy
79%
2x Hold
14%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Altimmune forecast:

Buy
79%
Hold
14%
Sell
7%

Financial data from Altimmune

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.02 0.02
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
10% 10%
108,700%
- Research and Development Expense 73 73
7% 7%
363,250%
-94 -94
14% 14%
-471,200%
- Depreciation and Amortization 0.13 0.13
80% 80%
650%
EBIT (Operating Income) EBIT -94 -94
14% 14%
-471,850%
Net Profit -88 -88
13% 13%
-438,750%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Head office United States
Employees 59
Website altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today